Two markets, one molecule
Glutathione is unusual in this category because it is sold through a channel that looks clinical. IV drip bars, wellness clinics and med spas offer it by infusion, often alongside vitamin blends, with a nurse present and a price list on the wall.
That presentation implies a medical evidence base. There is one, and it is not the one being sold.
What the registered record covers
ClinicalTrials.gov returns around 47 studies for glutathione injection, distributed across the phases the way a genuine clinical portfolio is: roughly eleven Phase 2, six Phase 3, five Phase 1, four Phase 4, plus a group registered as not applicable.
The titles are the informative part. Chemotherapy-resistant ovarian cancer. Advanced hepatocellular carcinoma. Male infertility with a nutritional supplement combination. Oncology, hepatology, reproductive medicine.
Titles mentioning skin, whitening, lightening or pigmentation come to about two out of forty-seven. The cosmetic use that drives almost all the search demand is close to absent from the trial record.
Why a clinical setting is not the same as a clinical indication
A pharmacy dispensing an approved medicine hands over a product whose indication a regulator authorised. A clinic administering an infusion is providing a service, and the setting does not carry an indication with it.
So the comparison worth making is not whether a nurse is present. It is whether the reason for the infusion appears anywhere in the approved or registered record for that purpose, and for cosmetic glutathione it largely does not.
A glutathione injection dosage chart is useful when each figure names the study, the population and the route it came from. Those attachments are what let a reader see that a quantity from a hepatocellular carcinoma protocol is not a cosmetic dose, which is invisible once it is just a number in a row.